Atogepant

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Glaucoma Risk Associated With Calcitonin Gene-Related Peptide Inhibitor Use in Migraine: A Multinational Cohort Study.

Glaucoma Risk Associated With Calcitonin Gene-Related Peptide Inhibitor Use in Migraine: A Multinational Cohort Study.

Journal: Neurology

Published: May 06, 2026

Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.

Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.

Journal: Annals of internal medicine

Published: May 04, 2026

Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.

Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.

Journal: The journal of headache and pain

Published: April 21, 2026

Effectiveness and tolerability of pharmacological prophylaxis in migraine patients with prior preventive treatment failure: A systematic review and network meta-analysis of randomized controlled trials.

Effectiveness and tolerability of pharmacological prophylaxis in migraine patients with prior preventive treatment failure: A systematic review and network meta-analysis of randomized controlled trials.

Journal: Cephalalgia : an international journal of headache

Published: April 21, 2026

Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.

Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE.

Journal: Neurology and therapy

Published: April 08, 2026

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

Journal: Cephalalgia : an international journal of headache

Published: April 07, 2026

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).

Journal: Cephalalgia : an international journal of headache

Published: April 01, 2026

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

Journal: Cephalalgia : an international journal of headache

Published: March 25, 2026

Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant-Treated Migraine Cohort.

Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant-Treated Migraine Cohort.

Journal: Journal of clinical medicine

Published: February 12, 2026

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Journal: Pain physician

Published: February 02, 2026

Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans.

Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans.

Journal: Clinical and translational science

Published: January 30, 2026

Drugs for Migraine Prophylaxis.

Drugs for Migraine Prophylaxis.

Journal: Deutsches Arzteblatt international

Published: January 23, 2026

Showing 1-12 of 189

Last Updated: 06/30/2026